Comparative randomized pilot study of azithromycin and doxycycline efficacy and tolerability in the treatment of prostate infection caused by Ureaplasma urealyticum

Chemotherapy

Volumn 52, Issue 1, 2005, Pages 9-11

  Škerk, Višnja ^a   Mareković, Ivana ^b   Markovinović, Leo ^a   Begovac, Josip ^a   Škerk, Vedrana ^c   Baršić, Neven ^c   Majdak Gluhinić, Vida ^a  

^a Croatia   (Croatia)

^b Hospital for Pulmonary Diseases

^c UNIVERSITY OF ZAGREB   (Croatia)

Author keywords

Azithromycin; Doxycycline; Prostatitis syndrome; Ureaplasma urealyticum

Indexed keywords

AZITHROMYCIN; DOXYCYCLINE;

ADULT; AGE DISTRIBUTION; ARTICLE; CLINICAL FEATURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG TOLERABILITY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MICTURITION; NAUSEA; PRIORITY JOURNAL; PROSTATITIS; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL; SEXUALITY; UREAPLASMA UREALYTICUM; URINALYSIS;

ADULT; AZITHROMYCIN; DOXYCYCLINE; FEMALE; HUMANS; MALE; PILOT PROJECTS; UREAPLASMA INFECTIONS; UREAPLASMA UREALYTICUM;

EID: 29344457395     PISSN: 00093157     EISSN: None     Source Type: Journal    
DOI: 10.1159/000090234     Document Type: Article

References (12)

1. Naber KG, Weidner W: Prostatitis, epididymitis and orchitis; in Cohen J, Powderly WG (eds): Infectious Diseases. Edinburgh, Mosby, 2004, pp 745-750.
2. Brunner H, Weidner W, Schiefer HG: Studies on the role of U. urealyticum and Mycoplasma hominis in prostatitis. J Infect Dis 1983;147:807-813.
3. Skerk V, Krhen I, Schonwald S, Cajic V, Markovinovic L, Roglic S, Zekan S, Andracevic AT, Kruzic V: The role of unusual pathogens in prostatitis syndrome. Int J Antimicrob Agents 2004;245:53-56.
4. Weidner W, Schiefer HG, Krauss H, Jantos C, Friedrich HJ, Altmannsberger M: Chronic prostatitis: A thorough search for etiologically involved microorganisms in 1,461 patients. Infection 1991;19(suppl 3):119-125.
5. Charalabopoulos K, Karachalios G, Baltogiannis D, Charalabopoulos A, Giannakopoulos X, Sofikitis N: Penetration of antimicrobial agents into the prostate. Chemotherapy 2003;49:269-279.
6. Boerena JBJ, Dalhoff A, Debruyne FMY: Ciprofloxacin distribution in prostatic tissue and fluid following oral administration. Chemotherapy 1985;31:13-18.
7. Sivapalasingam S, Steigbigel NH: Macrolides, clindamycin, and ketolides; in Mandell GL, Bennett JE, Dolin R (eds): Mandell, Douglas, and Bennett's Principles and Practice of Infectious Diseases. Philadelphia, Elsevier, Churchill Livingstone 2005, pp 396-417.
8. Skerk V, Schonwald S, Krhen I, Strapac Z, Markovinovic L, Kruzic V, Puntaric A, Vrsalovic R, Vukovic J: Azithromycin in the treatment of chronic prostatitis caused by Chlamydia trachomatis. J Chemother 2001;13:664-665.
9. Skerk V, Schonwald S, Krhen I, Markovinovic L, Barsic B, Marekovic I, Roglic S, Zeljko Z, Vince A, Cajic V: Comparative analysis of azithromycin and clarithromycin efficacy and tolerability in the treatment of chronic prostatitis caused by Chlamydia trachomatis. J Chemother 2002;14:384-389.
10. Skerk V, Schonwald S, Rrhen I, Banaszak A, Begovac J, Strugar J, Strapac Z, Vrsalovic R, Vukovic J, Tomas M: Comparative analysis of azithromycin and ciprofloxacin in the treatment of chronic prostatitis caused by Chlamydia trachomatis. Int J Antimicrob Agents 2003;21:457-462.
11. Skerk V, Krhen I, Lisic M, Begovac J, Cajic V, Zekan S, et al: Azithromycin: 4.5- or 6.0-gram dose in the treatment of patients with chronic prostatitis caused by Chlamydia trachomatis - a randomized study. J Chemother 2004;16:408-410.
12. Skerk V, Krhen I, Lisic M, Begovac J, Roglic S, Skerk V, Sternak SL, Banaszak A, Strugar-Suica J, Vukovic J: Comparative randomized pilot study of azithromycin and doxycycline efficacy and tolerability in the treatment of prostate infection caused by Chlamydia trachomatis. Int J Antimicrob Agents 2004;24:188-191.